Trial · NCT00763412

Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis

NCT00763412, Not applicable, Completed, Arbelaez, Ana Maria; results first posted 2017-06-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis. Trials, record NCT00763412. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00763412

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
NCT number: NCT00763412
Status: Completed
Phases: Not applicable
Enrollment: 31 participants, actual
Lead sponsor: Arbelaez, Ana Maria
Conditions: Cystic Fibrosis Related Diabetes, Pancreatic Insufficiency
Interventions: placebo, repaglinide
First posted: 2008-10-01
Last updated: 2017-06-05
Results first posted: 2017-06-05
Limitations and caveats: A limitation of the study was the very small sample size.

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	BMI	2 year/end of study
Primary	Body Composition	2 year/end of study	Reporting % of Fat and Lean body mass
Primary	CRP	2 year/end of study
Secondary	Glucose Tolerance	2-year	We completed the OGTT at the 2 year/end of study visit.
Secondary	Inflammatory Markers	2 year/end of study
Secondary	Wt Z Score	2 year/end of study
Secondary	Tanner Stage	2 year/end of study	Puberty scale measuring 1-5, 1 being least development, 5 being most development.
Secondary	FEV 1	2 year/end of study	% of lung function
Secondary	C-Peptide	2 year

Source ClinicalTrials.gov

Outcomes9

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	BMI	2 year/end of study	Kg/m^2	MEAN
PRIMARY	Body Composition	2 year/end of study	% body mass	MEAN
PRIMARY	CRP	2 year/end of study	mg/L	MEAN
SECONDARY	Glucose Tolerance	2-year	mg/dl	MEAN
SECONDARY	Inflammatory Markers	2 year/end of study	pg/ml	MEAN
SECONDARY	Wt Z Score	2 year/end of study	Z score	MEAN
SECONDARY	Tanner Stage	2 year/end of study	units on a scale	MEAN
SECONDARY	FEV 1	2 year/end of study	% lung function	MEAN
SECONDARY	C-Peptide	2 year	pg/ml	MEAN

Source ClinicalTrials.gov

Results by group30

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
BMI	1 Placebo		19.63	Full Range 15.56 to 22.64	Kg/m^2
BMI	2. Repaglinide		21.19	Full Range 20.78 to 21.8	Kg/m^2
Body Composition	1 Placebo	Fat	19.82	Full Range 12 to 37.8	% body mass
Body Composition	2. Repaglinide	Fat	26.21	Full Range 8.78 to 34.26	% body mass
Body Composition	1 Placebo	Lean	77.15	Full Range 59.54 to 87.84	% body mass
Body Composition	2. Repaglinide	Lean	70.83	Full Range 62.82 to 87.8	% body mass
CRP	1 Placebo		9.6	Full Range 0.7 to 27.5	mg/L
CRP	2. Repaglinide		2	Full Range 0.6 to 3.7	mg/L
Glucose Tolerance	1 Placebo	fasting glucose	101.5	Full Range 91 to 121	mg/dl
Glucose Tolerance	2. Repaglinide	fasting glucose	94.5	Full Range 85 to 108	mg/dl

1 to 10 of 30Source ClinicalTrials.gov

See all 30 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	8
Overall Study	STARTED	2. Repaglinide	8
Overall Study	COMPLETED	Placebo	4
Overall Study	COMPLETED	2. Repaglinide	4
Overall Study	NOT COMPLETED	Placebo	4
Overall Study	NOT COMPLETED	2. Repaglinide	4

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Placebo	8
Total, all-cause mortality	Repaglinide	8
Total, other adverse events	Placebo	8
Total, other adverse events	Repaglinide	8
Total, serious adverse events	Placebo	8
Total, serious adverse events	Repaglinide	8

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P60DK020579	Diabetes Research & Training Center	SCHAFFER, JEAN E.	WASHINGTON UNIVERSITY	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES	1986 to 2012

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Repaglinide vs Placebo: deaths from any cause	Trial comparisons
Repaglinide vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00763412

GET https://conductscience.org/api/trials/v1/NCT00763412/results?page=2

API reference For AI assistants